Analysed OCULIS HOLDING AG (OCS:NASDAQ) News Sources
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
29-05-2026
yahoo.com
Oculis Holding AG Phase 3 Trial of Potential Eye Drops for Diabetic Patients Fails to Primary Endpoint
29-05-2026
yahoo.com
OCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses Target
29-05-2026
stocktwits.com
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
08-06-2026
yahoo.com
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
09-06-2026
yahoo.com
What is the current price of OCULIS HOLDING AG (OCS:NASDAQ)?
The current price of OCULIS HOLDING AG (OCS:NASDAQ) is $13.63.
OCULIS HOLDING AG (OCS:NASDAQ) absolute price change since previous trading day?
The absolute price change of OCULIS HOLDING AG (OCS:NASDAQ) since the previous trading day is $-0.07.
OCULIS HOLDING AG (OCS:NASDAQ) percentage price change since previous trading day?
The percentage price change of OCULIS HOLDING AG (OCS:NASDAQ) since the previous trading day is -0.5109%.
What is the most recent average sentiment score for OCULIS HOLDING AG (OCS:NASDAQ)?
The most recent average sentiment score for OCULIS HOLDING AG (OCS:NASDAQ) is 66 out of 100.
What is the most recent average sentiment for OCULIS HOLDING AG (OCS:NASDAQ)?
The most recent sentiment for OCULIS HOLDING AG (OCS:NASDAQ) is .
SEC-8K** Filing Available For OCULIS HOLDING AG (OCS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.